Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Studies assess 2-year and sustained-release ONO-5334 therapy

Oct. 4, 2011

Eisai evaluates new anticoagulants in human microdosing study

Oct. 3, 2011

Bacterial DNA minor groove binder shows promise against CDI-associated diarrhea

Oct. 3, 2011

Scientists identify SNP associated with increased susceptibility to bacterial meningitis

Oct. 3, 2011

Final first-in-human data presented on CureVac's prostate cancer mRNA vaccine

Oct. 3, 2011

Summit presents preclinical data on antimicrobial agents targeting CDI

Oct. 3, 2011

Multifunctional fusion protein prevents HIV infection in vivo

Sep. 30, 2011

Phase II trial investigates safety/efficacy of AZD-3199 in COPD

Sep. 30, 2011

Ibalizumab shows promise in phase IIb study

Sep. 30, 2011

Eisai's broad-spectrum antifungal agents display preclinical promise

Sep. 30, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...